Abstract: TH-PO246
Moisturizer Improves Pruritus in Dialysis Patients by Increasing Water Content in the Stratum Corneum: A Multicenter, Randomized, Confirmatory Study
Session Information
- Hemodialysis and Frequent Dialysis - II
November 07, 2019 | Location: Exhibit Hall, Walter E. Washington Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Yoshida, Yukie, Kidney Clinic, Nippon Medical School, Tokyo, Japan
- Hirama, Akio, Kidney Clinic, Nippon Medical School, Tokyo, Japan
- Hashimoto, Kazumasa, Kidney Clinic, Nippon Medical School, Tokyo, Japan
- Sato, Takeshi, Koyama Memorial Hospital, Ibaraki, Japan
- Yokota, Noritsugu, Moka Hospital, Tochigi, Japan
- Saeki, Hidehisa, Nippon Medical School, Tokyo, Japan
- Kishida, Momoyo, Maruho Co., Ltd., Osaka, Japan
- Kanakubo, Akira, Maruho Co., Ltd., Osaka, Japan
- Tsuruoka, Shuichi, Nippon Medical School, Tokyo, Japan
Background
Dialysis patients often have skin dryness and pruritus that are treated with moisturizers without sufficient evidence. We had reported an exploratory study on the efficacy of a heparinoid moisturizer for asteatosis in dialysis patients at Kidney Week 2017. In this confirmatory study, the efficacy and safety of additional 4-week treatment was evaluated in a larger population.
Methods
This study was an open-label, randomized, before-after, parallel group comparison, multi-center study conducted after approval by the Institutional Review Board. The study was funded by Maruho Co., Ltd., and registered at the University Hospital Medical Information Network (ID: UMIN000029360). In total, 71 Japanese chronic renal failure patients on dialysis with asteatosis applied a topical heparinoid (Maruho) twice a day on dryness/pruritus areas, including the lower ribs where water content in stratum corneum (WCSC) was measured using a Corneometer (Courage+Khazaka, Cologne, Germany), at proper dose by finger-tip unit for 2 weeks in Group A and 8 weeks in Group B. The primary endpoint was WCSC at Week 4 and secondary were trends in WCSC, pruritus visual analogue scale (VAS), dryness symptoms and dermatology life quality index (DLQI). Safety endpoint was adverse events (AEs).
Results
WCSC at Week 4 of group B (n=35) was significantly higher than Group A (n=36). WCSC, pruritus VAS and dryness symptoms improved until Week 2 in both groups. After Week 2, improvement sustained in Group B, but exacerbated in Group A. DLQI showed the same trend, especially in “symptoms and feelings” subscale. AEs occurred in 51 patients (107 events); 1 patient had treatment-related rash/eruption.
Conclusion
Heparinoid moisturizer increased WCSC, which subsequently improved pruritus and QOL. Continuous treatment at proper dose is necessary to maintain efficacy for asteatosis and pruritus in dialysis patients.
Funding
- Commercial Support –